Bioenvision Continues Buildout of Sales and Marketing Infrastructure; Appoints UK Sales Manager, a Medical Information Manager and Six UK Sales Representatives.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- Bioenvision (Nasdaq: BIVN) announced today that it has appointed a UK Sales Manager sales manager n → gerente m/f de ventas sales manager n → directeur commercial sales manager sale n → , a Medical Information Manager and six UK specialist oncology sales representatives. Mr. Robert Bradbury Robert Bradbury is a transhumanist who is known for inventing the concept of the Matrioshka Brain. He graduated in applied mathematics in Harvard and microbiology from the University of Washington. He currently works in the field of life extension. External Link Robert Bradbury's Homepage , formerly a National Business Manager-Oncology at Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were Pharmaceuticals, has been appointed to the position of UK Sales Manager and Ms. Katy Porter, formerly a Medical Information Officer at Cambridge Laboratories Ltd, has been appointed to the position of Medical Information Manager. In addition, Bioenvision appointed six UK specialist oncology sales representatives and anticipates appointing additional sales representatives in Europe over the next six months. The specialist oncology sales team has significant sales experience at leading pharmaceutical companies including Astrazeneca, Bristol Myers Squibb, Novartis, Ortho-Biotech and Chiron. Commenting on the new appointments, Hugh Griffith, Bioenvision's Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. said, "our ability to attract and retain highly qualified professionals from major pharmaceutical companies is further confirmation of the commercial potential of our products and technologies." About Bioenvision Bioenvision's (Nasdaq: BIVN) primary focus is the development and distribution of compounds and technologies for the treatment of cancer. Bioenvision has a broad pipeline of products for the treatment of cancer, including: clofarabine (in co-development with ILEX Ilex a bush bearing berries containing saponins; cause vomiting, diarrhea. Called also holly. Oncology, Inc.), Modrenal(R) (for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy Hormone therapy Treating cancers by changing the hormone balance of the body, instead of by using cell-killing drugs. Mentioned in: Breast Cancer, Thyroid Cancer hormone therapy ), and other products in clinical trials. Bioenvision is also developing anti-infective technologies, including the OLIGON technology; an advanced biomaterial biomaterial /bio·ma·te·ri·al/ (bi?o-mah-ter´e-al) a synthetic dressing with selective barrier properties, used in the treatment of burns; it consists of a liquid solvent (polyethylene glycol-400) and a powdered polymer. that has been incorporated into various FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approved medical devices. For more information on Bioenvision please visit our Web site at www.bioenvision.com. Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and in Bioenvision's compounds under development in particular; the potential failure of Bioenvision's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Bioenvision's compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Bioenvision's business, structure or projections; the development of competing products; uncertainties related to Bioenvision's dependence on third parties and partners; and those risks described in Bioenvision's filings with the SEC. Bioenvision disclaims any obligation to update these forward-looking statements. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion